This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
etfs: Archive
Best-Performing ETFs of Last Week: Healthcare Rules
by Sanghamitra Saha
Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.
etfs
Should You Boost Your Allocation to Growth ETFs Now?
by Yashwardhan Jain
Growth ETFs stand out as growth forecasts rise, Fed cut hopes build and investors pour billions back into U.S. equities.
etfs
Corporate Bond ETF (BSCQ) Hits Fresh 52-Week High
by Zacks Equity Research
BSCQ hits a new 52-week high as investors pivot to safety assets amid lower rates and tightening credit spreads.
etfs
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
by Sanghamitra Saha
Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.
etfs pharmaceuticals
The Zacks Analyst Blog SPDR Gold Trust, HDGE, PGHY and XLV
by Zacks Equity Research
GLD gains attention as AI bubble fears rise, with investors eyeing hedges and ETFs geared toward market downside protection.
etfs
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
by Aparajita Dutta
LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
etfs pharmaceuticals
Spotlight on European ETFs Ahead of Expected BoE December Rate Cut
by Aparajita Dutta
A potential December rate cut from the BoE raises fresh questions for ETFs heavily exposed to UK banks like Allianz.
etfs finance
US Approves $93M Weapon Sale to India: A Boost for Defense ETFs
by Aparajita Dutta
A $93 million US weapon sale to India puts the spotlight on defense stocks like LMT and, by extension, fuels momentum for defense ETFs like SHLD.
aerospace etfs
Rare Earth ETFs Gain Momentum Amid Arctic Metal Push
by Yashwardhan Jain
REMX jumps as global demand for rare earths surges and investors eye Arctic resources amid rising geopolitical interest.
etfs
Inside the Recent Strength in Biotech ETFs
by Sanghamitra Saha
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
biotechnology etfs